source
- Gene editing developer Scribe plots an IPOThe California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.BioPharma Dive · 23d ago↗ source
- Novartis to acquire ADC developer in a deal worth up to $1.5BThe deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.BioPharma Dive · 23d ago↗ source
- STAT+: Four major biotech updates to catch up onAnthropic CEO talks drug discovery, Medicare proposes steep 340B drug payment cuts, and more biotech newsSTAT · 23d ago↗ source